TY - JOUR
T1 - Aging population and future burden of pneumococcal pneumonia in the United States
AU - Wroe, Peter C.
AU - Finkelstein, Jonathan A.
AU - Ray, G. Thomas
AU - Linder, Jeffrey A.
AU - Johnson, Kristen M.
AU - Rifas-Shiman, Sheryl
AU - Moore, Matthew R.
AU - Huang, Susan S.
N1 - Funding Information:
Financial support. This work was supported by the CDC (grant number TS-1363 to J. A. F.).
Funding Information:
Potential conflicts of interest. J. A. L. has received research grants from Pfizer to study electronic adverse drug event reporting and Roche to study use of anti-influenza medications. G. T. R. has received research support from Pfizer, GlaxoSmithKline, and Merck. All other authors report no potential conflicts.
PY - 2012/5/15
Y1 - 2012/5/15
N2 - Pneumococcal pneumonia is concentrated among the elderly. Using a decision analytic model, we projected the future incidence of pneumococcal pneumonia and associated healthcare utilization and costs accounting for an aging US population. Between 2004 and 2040, as the population increases by 38, pneumococcal pneumonia hospitalizations will increase by 96 (from 401 000 to 790 000), because population growth is fastest in older age groups experiencing the highest rates of pneumococcal disease. Absent intervention, the total cost of pneumococcal pneumonia will increase by $2.5 billion annually, and the demand for healthcare services for pneumococcal pneumonia, especially inpatient capacity, will double in coming decades.
AB - Pneumococcal pneumonia is concentrated among the elderly. Using a decision analytic model, we projected the future incidence of pneumococcal pneumonia and associated healthcare utilization and costs accounting for an aging US population. Between 2004 and 2040, as the population increases by 38, pneumococcal pneumonia hospitalizations will increase by 96 (from 401 000 to 790 000), because population growth is fastest in older age groups experiencing the highest rates of pneumococcal disease. Absent intervention, the total cost of pneumococcal pneumonia will increase by $2.5 billion annually, and the demand for healthcare services for pneumococcal pneumonia, especially inpatient capacity, will double in coming decades.
UR - http://www.scopus.com/inward/record.url?scp=84860372845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860372845&partnerID=8YFLogxK
U2 - 10.1093/infdis/jis240
DO - 10.1093/infdis/jis240
M3 - Article
C2 - 22448012
AN - SCOPUS:84860372845
VL - 205
SP - 1589
EP - 1592
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 10
ER -